Samsung Biologics records revenue of KRW 127.5 billion and
operating profits of KRW 20.5 billion in 3Q 2017
- Revenue and Operating profits increased due to full operation of Plant 1 and increased operation rates of plant 2.
Samsung Biologics Co., Ltd. (CEO: Tae Han Kim) today announced its financial results for the third quarter of 2017. The company posted quarterly revenue of KRW 127.5 billion and quarterly operating profits of KRW 20.5 billion.
Revenue of Samsung Biologics increased KRW 64.3billion as its first plant continues to fully operate and the operation rate of its second plant keeps increasing. Net loss recorded KRW 31.7 billion, declined KRW 9.6 billion QOQ, reflecting of call option valuation losses on its subsidiary company and a slight increase in equity method loss on subsidiaries.
※ Samsung Biologics Financial Result 3Q 2017 (Billion KRW)
| 3Q 17 | 2Q 17 | QoQ |
Revenue | 127.5 | 63.2 | 64.3 |
Operating Profit | 20.5 | -8.5 | 29 |
Net Profit | -31.7 | -22.1 | -9.6 |
- The End -
Samsung Biologics records revenue of KRW 127.5 billion and
operating profits of KRW 20.5 billion in 3Q 2017
- Revenue and Operating profits increased due to full operation of Plant 1 and increased operation rates of plant 2.
Samsung Biologics Co., Ltd. (CEO: Tae Han Kim) today announced its financial results for the third quarter of 2017. The company posted quarterly revenue of KRW 127.5 billion and quarterly operating profits of KRW 20.5 billion.
Revenue of Samsung Biologics increased KRW 64.3billion as its first plant continues to fully operate and the operation rate of its second plant keeps increasing. Net loss recorded KRW 31.7 billion, declined KRW 9.6 billion QOQ, reflecting of call option valuation losses on its subsidiary company and a slight increase in equity method loss on subsidiaries.
※ Samsung Biologics Financial Result 3Q 2017 (Billion KRW)
| 3Q 17 | 2Q 17 | QoQ |
Revenue | 127.5 | 63.2 | 64.3 |
Operating Profit | 20.5 | -8.5 | 29 |
Net Profit | -31.7 | -22.1 | -9.6 |
- The End -
- CDO
- CGMP
- ADC
- Bio Campus
- IR
- CMO
Share article